Dynavax Technologies

Dynavax Technologies is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses by developing cutting-edge vaccines and utilizing our innovative adjuvant technology as well as our expertise in Toll-like Receptor (TLR) biology. We are committed to a rigorous approach to drug development in the field of TLR biology so that we may help physicians and patients address unmet needs. Dynavax is currently marketing the only 2-dose, administered over 1-month, Hepatitis B vaccine for adults, 18 years and older; Heplisav-B.

Learn More About:       Dynavax      Prevention of Hepatitis B      Presentation on Hepatitis B

Contact Dynavax Technologies:
Kurt Marrs